- Home
- SCZM vs IMMX Comparison
SCZM vs IMMX Comparison
Compare SCZM & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCZM | IMMX |
|---|---|---|
| Founded | N/A | 2014 |
| Country | Canada | United States |
| Employees | 455 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.7M | 629.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SCZM | IMMX |
|---|---|---|
| Price | $7.57 | $8.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $12.00 | ★ $19.20 |
| AVG Volume (30 Days) | 479.1K | ★ 1.3M |
| Earning Date | 05-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.38 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.90 | $1.94 |
| 52 Week High | $17.65 | $11.61 |
Technical Indicators
Market Signals| Indicator | SCZM | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 42.24 |
| Support Level | $7.17 | $8.10 |
| Resistance Level | $10.15 | $8.97 |
| Average True Range (ATR) | 0.51 | 0.76 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 3.94 | 20.04 |
Price Performance
Historical ComparisonAbout SCZM Santacruz Silver Mining Ltd. Common Shares
Santacruz Silver Mining Ltd is engaged in the operation, acquisition, exploration, and development of mineral properties in Latin America, with a primary focus on silver and zinc, including lead and copper. The company earns the majority of its revenue from Zinc and Silver. The company's reportable operating segments are the Bolivar mine and processing plant, the Porco mine and processing plant, the Caballo Blanco Group, San Lucas, Zimapa mine and processing plant, and Corporate and Other activities. Key revenue is generated from Zimapan.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.